Literature DB >> 3397968

Endomyocardial biopsy in patients with systemic lupus erythematosus.

M J Fairfax1, T G Osborn, G A Williams, C C Tsai, T L Moore.   

Abstract

Systemic lupus erythematosus (SLE) has numerous cardiovascular manifestations. Myocarditis is present in more than 50% of patients with SLE at autopsy, but it may be silent clinically during life. Percutaneous endomyocardial biopsy performed in 4 patients with SLE was found helpful in establishing the diagnosis and in determining the extent of the inflammatory myocarditis. The findings aided the regulation of therapy, particularly the administration of immunosuppressive drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3397968

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

2.  Sub-clinical systemic lupus erythematosus presenting with acute myocarditis.

Authors:  K Sandrasegaran; C W Clarke; V Nagendran
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

3.  Acute myocarditis and ventricular fibrillation as initial presentation of pediatric systemic lupus erythematosus.

Authors:  Chi-Nan Huang; Hsin-Hui Yu; Shuenn-Nan Chiu; Jyh-Hong Lee; Li-Chieh Wang; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Rheumatol Int       Date:  2011-11-26       Impact factor: 3.580

4.  Aggressive cardiac involvement in systemic lupus erythematosus: a case report and a comprehensive literature review.

Authors:  Reza Ashrafi; Pankaj Garg; Ewan McKay; John Gosney; Som Chuah; Gershan Davis
Journal:  Cardiol Res Pract       Date:  2011-02-15       Impact factor: 1.866

Review 5.  The spectrum of lupus myocarditis: from asymptomatic forms to cardiogenic shock.

Authors:  Maya Guglin; Carson Smith; Roopa Rao
Journal:  Heart Fail Rev       Date:  2020-11-19       Impact factor: 4.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.